StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on OKYO Pharma Ltd. (OKYO)

Wed, 07 Oct 2026 06:50:52 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $7.00 price target on OKYO Pharma Ltd. (NASDAQ: OKYO).

The analyst commented: "This morning, OKYO Pharma announced that the first patients have been enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP). Neuropathic corneal pain (NCP) is a chronic and debilitating condition characterized by severe pain and sensitivity of the eyes, which may result from damage or dysfunction of the corneal sensory nerves. NCP has no FDA-approved treatment options, thus representing a significant unmet medical need for patients. The first clinical site has been activated at

OKYO Pharma enrolls first patients in Phase 3 corneal pain trial

Tue, 06 Oct 2026 07:00:25 -0400

OKYO Pharma Limited (Nasdaq: OKYO) announced that the first patients have been enrolled in its Phase 3 NEPTUNE trial evaluating urcosimod as a treatment for neuropathic corneal pain (NCP), according to a company statement.

The first patients were enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, Tennessee. The trial is expected to expand to multiple sites across the United States and in Europe, including Italy, Spain, and France.

Neuropathic corneal pain is a chronic condition characterized by severe eye pain and sensitivity, which the company says has no FDA-approved treatment options. The condition is thought to result from damage or

Form 6-K OKYO Pharma Ltd For: Oct 06

Tue, 06 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27151671.html

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

Tue, 06 Oct 2026 07:00:00 -0400

NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain
First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN

LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).

"Neuropathic corneal pain is one of the most debilitating conditions I see in my

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

Tue, 06 Oct 2026 07:00:00 -0400

NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain
First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN

"Neuropathic corneal pain is one of the most debilitating conditions I see in my

Form 6-K OKYO Pharma Ltd For: Sep 29

Tue, 29 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27117190.html

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

Tue, 29 Sep 2026 07:00:00 -0400

OKYO demonstrates continued commitment to optometry and ophthalmology

LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.

Upcoming Scientific Conferences:

Eyecelerator: October 8, 2026
New Orleans, Louisiana

Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases
Presentation Date/Time: Thursday, October 8, 2026, 1:29 PM CT
Breakout: Anterior Segment, Room 243-245
Presenter:

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

Tue, 29 Sep 2026 07:00:00 -0400

OKYO demonstrates continued commitment to optometry and ophthalmology

Upcoming Scientific Conferences:

Eyecelerator: October 8, 2026
New Orleans, Louisiana

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

Wed, 09 Sep 2026 07:00:00 -0400

Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain

LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.

Ophthalmology Futures European Forum on Thursday, September 10 in London is where clinical innovators, investors, and industry leaders

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

Wed, 09 Sep 2026 07:00:00 -0400

Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain

Ophthalmology Futures European Forum on Thursday, September 10 in London is where clinical innovators, investors, and industry leaders

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

Tue, 08 Sep 2026 07:00:00 -0400

LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026.

Details of the event are as follows:

Presenters: Flavio Mantelli, MD, PhD, Chief Medical Officer, Gary Jacob, PhD, Chief Development Officer

Date/Time: Thursday, September 10 at 8:35 AM ET

Moderator: Eric Fitzgerald, Cantor Fitzgerald

The Company will be available for one-on-one

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

Tue, 08 Sep 2026 07:00:00 -0400

Details of the event are as follows:

Presenters: Flavio Mantelli, MD, PhD, Chief Medical Officer, Gary Jacob, PhD, Chief Development Officer

Date/Time: Thursday, September 10 at 8:35 AM ET

Moderator: Eric Fitzgerald, Cantor Fitzgerald

The Company will be available for one-on-one

Form 20-F/A OKYO Pharma Ltd For: Mar 31

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891540.html

Form 20-F/A OKYO Pharma Ltd For: Mar 31

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891540.html

Form 4/A OKYO Pharma Ltd For: Jul 21 Filed by: BRANCACCIO JOHN P